Mary J Bossard

This inventor holds 40 USPTO granted patents and 28 published patent applications, plus 12 CIPO patents and 14 EPO patents, primarily in Polymer Conjugates. Top assignees: Nektar Therapeutics, Baxalta Gmbh, Baxter Healthcare Sa. Active years: 2007-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mary J Bossard. Retrieved from https://idiyas.com/inventor/mary-j-bossard

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 40 (Patent Applications = 28)

% Patents Active = 75.0

CIPO Patents = 12

EPO Patents = 14 (Patent Applications = 19)

Average Co-Inventor Count = 2.8

ph-index = 9

Forward Citations = 357(Granted Patents)

Location History:

Alabama, AL (US) (2012)
Madison, AL (US) (2007 - 2023)

Company Filing History:

Baxter International Inc.

patents

5. 2 out of 45

Nektar Therapeutics Al, Corporation

where one patent can have more than one assignee

Years Active: 2007-2025

Loading Chart...

Areas of Expertise:

Polymer Conjugates

Factor VIII

IL-2 Moieties

Therapeutic Peptides

Anti-TNF-alpha Antibody

Protegrin Peptides

Bioactive Peptides

Nesiritide Peptides

Von Willebrand Factor

Active Agent Conjugates

Releasable Linkage

Antimicrobial Agents

40 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12324828 - Conjugates of a factor VIII moiety having an oxime-containing linkage (2025-06-10),

2. 12247059 - Conjugates of an IL-2 moiety and a polymer (2025-03-11),

3. 11628205 - Conjugates of a factor VIII moiety having an oxime-containing linkage (2023-04-18),

4. 11141465 - Method of making a water-soluble polymer-factor VIII moiety conjugate (2021-10-12),

5. 10960079 - Conjugates of an IL-2 moiety and a polymer (2021-03-30),

6. 10232042 - Conjugates of an anti-TNF-alpha antibody (2019-03-19),

7. 9999657 - Polymer-factor VIII moiety conjugates (2018-06-19),

8. 9861705 - Conjugates of an IL-2 moiety and a polymer (2018-01-09),

9. 9763995 - Polymer conjugates of protegrin peptides (2017-09-19),

10. 9682153 - Polymer conjugates of therapeutic peptides (2017-06-20),

11. 9636412 - Conjugates of an anti-TNF-alpha antibody (2017-05-02),

12. 9539337 - Compositions comprising two different populations of polymer-active agent conjugates (2017-01-10),

13. 9493544 - Von willebrand factor- and factor VIII-polymer conjugates having a releasable linkage (2016-11-15),

14. 9347054 - Polymer factor IX moiety conjugates (2016-05-24),

15. 9274122 - Methods for determining active ingredients in pro-drug PEG protein conjugates with releasable PEG reagents (in vitro de-pegylation) (2016-03-01),

Title: Mary J Bossard - Pioneering Innovator in Biomedical Conjugates

Introduction:

Mary J Bossard is a distinguished inventor based in Madison, AL, with a remarkable portfolio of 38 patents in the field of biomedical conjugates. Her innovative work has significantly impacted the medical field, particularly in treatments involving Factor VIII molecules.

Latest Patents:

1. Conjugates of a Factor VIII moiety having an oxime-containing linkage.

2. Method of making a water-soluble polymer-Factor VIII moiety conjugate.

Career Highlights:

Mary's expertise shines through in her latest patents, showcasing her invaluable contributions to the development of conjugates involving Factor VIII molecules. These patents highlight her proficiency in creating novel biomedical solutions that have the potential to revolutionize medical treatments.

Collaborations:

Throughout her career, Mary has collaborated with esteemed companies such as Nektar Therapeutics and Baxalta GmbH. Her collaborations with talented individuals like Ping Zhang and Michael David Bentley have fostered a dynamic and innovative work environment, leading to groundbreaking inventions in the field of biomedical science.

Conclusion:

Mary J Bossard's dedication to innovation and her pioneering work in biomedical conjugates have solidified her reputation as a trailblazer in the field. Her patents stand as a testament to her ingenuity and unwavering commitment to advancing medical treatments for the betterment of society.

Profile summary based on public USPTO records.